Education
About Us
Working with TipRanks
Follow Us
Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
GSS Stock Chart & Stats
AU$0.24
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.24
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.12 - AU$0.69
Previous CloseN/A
Volume34.30K
Average Volume (3M)149.45K
Market Cap
AU$28.39M
Enterprise ValueAU$20.57M
Total Cash (Recent Filing)AU$31.30M
Total Debt (Recent Filing)AU$791.00K
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding227,138,820
10 Day Avg. Volume161,537
30 Day Avg. Volume149,454
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.65
Price to Sales (P/S)5.20
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary 3base™ TechnologyThe proprietary 3base™ platform underpins multiplex PCR assay development and associated workflows (software and lab integration). That platform creates product differentiation and a pathway to expand diagnostic menus, supporting durable IP-led competitive advantages and longer-term customer stickiness.
Consumables-driven Recurring ModelRevenue is driven by repeat consumable kit sales that scale with testing volume at customer labs. This annuity-style consumables model is structurally durable: once assays are adopted, ongoing purchases and validation barriers create recurring revenue and operating leverage as volumes increase.
Very Low Financial LeverageA near-zero debt profile gives balance-sheet flexibility to fund commercialization, R&D, and absorb operational volatility without high interest obligations. Low leverage materially reduces bankruptcy risk and supports strategic investments while cash flows remain weak.
Bears Say
Persistent UnprofitabilityConsistent negative net, EBIT and EBITDA margins indicate the business has not reached profitable scale. Long-term losses erode retained capital, suppress ROE and force reliance on external funding to sustain commercialization, hindering self-funded growth and margin improvement.
Negative Operating And Free Cash FlowSustained negative operating and free cash flows create cash burn that limits investments in sales, regulatory work and manufacturing scale. Even with some free cash flow improvement, persistent cash deficits elevate refinancing risk and constrain long-term commercialization execution.
Revenue Seasonality And Regulatory ExposureDemand depends on seasonal and outbreak-driven testing volumes and on regulatory/reimbursement approvals. That structural exposure makes revenues lumpy, slows steady adoption, and raises go-to-market friction in new jurisdictions, weakening predictability of scale and margins.
Genetic Signatures Ltd. News
GSS FAQ
What was Genetic Signatures Ltd.’s price range in the past 12 months?
Genetic Signatures Ltd. lowest share price was AU$0.12 and its highest was AU$0.69 in the past 12 months.
What is Genetic Signatures Ltd.’s market cap?
Genetic Signatures Ltd.’s market cap is AU$28.39M.
When is Genetic Signatures Ltd.’s upcoming earnings report date?
Genetic Signatures Ltd.’s upcoming earnings report date is Feb 26, 2026 which is in 5 days.
How were Genetic Signatures Ltd.’s earnings last quarter?
Genetic Signatures Ltd. released its earnings results on Aug 24, 2025. The company reported -AU$0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.022.
Is Genetic Signatures Ltd. overvalued?
According to Wall Street analysts Genetic Signatures Ltd.’s price is currently Overvalued.
Does Genetic Signatures Ltd. pay dividends?
Genetic Signatures Ltd. does not currently pay dividends.
What is Genetic Signatures Ltd.’s EPS estimate?
Genetic Signatures Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Signatures Ltd. have?
Genetic Signatures Ltd. has 227,138,820 shares outstanding.
What happened to Genetic Signatures Ltd.’s price movement after its last earnings report?
Genetic Signatures Ltd. reported an EPS of -AU$0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 14%.
Which hedge fund is a major shareholder of Genetic Signatures Ltd.?
Currently, no hedge funds are holding shares in AU:GSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genetic Signatures Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.35%
12-Months-Change
Fundamentals
Return on Equity
-36.16%
Trailing 12-Months
Asset Growth
-18.81%
Trailing 12-Months
Company Description
Genetic Signatures Ltd.
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
Inoviq Ltd
―